DNA methylation in neurodegenerative disorders: A missing link between genome and environment?

Clinical Genetics

Volumn 80, Issue 1, 2011, Pages 1-14

  Iraola Guzman S ^a   Estivill, X ^a,b   Rabionet, R ^a  

^a CENTRE FOR GENOMIC REGULATION CRG   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Aging; DNA methylation; Epigenetics; Neurodegeneration

Indexed keywords

ALPHA SYNUCLEIN; ANTIOXIDANT; APOLIPOPROTEIN E; BETA SECRETASE; CYANOCOBALAMIN; DNA METHYLTRANSFERASE; FOLIC ACID; GAMMA SECRETASE; HISTONE DEACETYLASE INHIBITOR; HOMOCYSTEINE; MEMBRANE METALLOENDOPEPTIDASE; OMEGA 3 FATTY ACID; S ADENOSYLHOMOCYSTEINE;

ALCOHOL CONSUMPTION; ALZHEIMER DISEASE; AUTOIMMUNE DISEASE; CALORIC RESTRICTION; CIGARETTE SMOKING; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DNA METHYLATION; DNA MODIFICATION; ELECTROMAGNETIC FIELD; ENVIRONMENTAL FACTOR; EPIGENETICS; EXERCISE; FRAGILE X SYNDROME; FRUIT; GAUCHER DISEASE; GENE EXPRESSION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC REGULATION; GENETIC RISK; GENETIC TRAIT; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HISTONE MODIFICATION; HUMAN; HUNTINGTON CHOREA; HYPERHOMOCYSTEINEMIA; LEARNING; LEWY BODY; MEMORY; MICROARRAY ANALYSIS; NEUROPROTECTION; PARKINSON DISEASE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; RETT SYNDROME; REVIEW; SUBSTANTIA NIGRA; TRAUMATIC BRAIN INJURY;

ALZHEIMER DISEASE; DNA METHYLATION; ENVIRONMENT; EPIGENESIS, GENETIC; GENOME, HUMAN; HUMANS; NUCLEOSOMES; PARKINSON DISEASE; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 79958170373     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2011.01673.x     Document Type: Review

References (197)

1. Landrigan PJ, Sonawane B, Butler RN et al. Early environmental origins of neurodegenerative disease in later life. Environ Health Perspect 2005: 113: 1230-1233.
2. Barker DJ. A new model for the origins of chronic disease. Med Health Care Philos 2001: 4: 31-35.
3. Lahiri DK, Maloney B. The "LEARn" (Latent Early-life Associated Regulation) model integrates environmental risk factors and the developmental basis of Alzheimer's disease, and proposes remedial steps. Exp Gerontol 2010: 45: 291-296.
4. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003: 33 (Suppl): 245-254.
5. Weaver IC, Cervoni N, Champagne FA et al. Epigenetic programming by maternal behavior. Nat Neurosci 2004: 7: 847-854.
6. Murgatroyd C, Patchev AV, Wu Y et al. Dynamic DNA methylation programs persistent adverse effects of early-life stress. Nat Neurosci 2009: 12: 1559-1566.
7. Waddington CH. The epigenotype. Endeavour 1942: 1: 18-20.
8. Wu C, Morris JR. Genes, genetics, and epigenetics: a correspondence. Science 2001: 293: 1103-1105.
9. Kouzarides T. Chromatin modifications and their function. Cell 2007: 128: 693-705.
10. Zaratiegui M, Irvine DV, Martienssen RA. Noncoding RNAs and gene silencing. Cell 2007: 128: 763-776.
11. Bai L, Morozov AV. Gene regulation by nucleosome positioning. Trends Genet 2010: 26: 476-483.
12. Jiang C, Pugh BF. Nucleosome positioning and gene regulation: advances through genomics. Nat Rev Genet 2009: 10: 161-172.
13. Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol 2010: 28: 1057-1068.
14. Robertson KD. DNA methylation and human disease. Nat Rev Genet 2005: 6: 597-610.
15. Chuang DM, Leng Y, Marinova Z et al. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci 2009: 32: 591-601.
16. Kalin JH, Butler KV, Kozikowski AP. Creating zinc monkey wrenches in the treatment of epigenetic disorders. Curr Opin Chem Biol 2009: 13: 263-271.
17. Fischer A, Sananbenesi F, Mungenast A, Tsai LH. Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol Sci 2010: 31: 605-617.
18. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006: 5: 525-535.
19. Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N Engl J Med 2003: 348: 1356-1364.
20. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006: 368: 387-403.
21. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet 2009: 373: 2055-2066.
22. Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: back to the future. Neuron 2010: 68: 270-281.
23. Hamza TH, Payami H. The heritability of risk and age at onset of Parkinson's disease after accounting for known genetic risk factors. J Hum Genet 2010: 55: 241-243.
24. Meissner A, Mikkelsen TS, Gu H et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 2008: 454: 766-770.
25. Takizawa T, Nakashima K, Namihira M et al. DNA methylation is a critical cell-intrinsic determinant of astrocyte differentiation in the fetal brain. Dev Cell 2001: 1: 749-758.
26. Hernandez DG, Nalls MA, Gibbs JR et al. Distinct DNA methylation changes highly correlated with chronological age in the human brain. Hum Mol Genet 2011: 20: 1164-1172.
27. Heijmans BT, Tobi EW, Lumey LH, Slagboom PE. The epigenome: archive of the prenatal environment. Epigenetics 2009: 4: 526-531.
28. Bernal AJ, Jirtle RL. Epigenomic disruption: the effects of early developmental exposures. Birth Defects Res A Clin Mol Teratol 2010: 88: 938-944.
29. Fraga MF, Ballestar E, Paz MF et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A 2005: 102: 10604-10609.
30. Eichler EE, Flint J, Gibson G et al. Missing heritability and strategies for finding the underlying causes of complex disease. Nat Rev Genet 2010: 11: 446-450.
31. Weaver IC, Champagne FA, Brown SE et al. Reversal of maternal programming of stress responses in adult offspring through methyl supplementation: altering epigenetic marking later in life. J Neurosci 2005: 25: 11045-11054.
32. McGowan PO, Suderman M, Sasaki A et al. Broad epigenetic signature of maternal care in the brain of adult rats. PLoS ONE 2011: 6: e14739.
33. McGowan PO, Sasaki A, D'Alessio AC et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci 2009: 12: 342-348.
34. Dolinoy DC, Huang D, Jirtle RL. Maternal nutrient supplementation counteracts bisphenol A-induced DNA hypomethylation in early development. Proc Natl Acad Sci U S A 2007: 104: 13056-13061.
35. Heijmans BT, Tobi EW, Stein AD et al. Persistent epigenetic differences associated with prenatal exposure to famine in humans. Proc Natl Acad Sci U S A 2008: 105: 17046-17049.
36. Tobi EW, Lumey LH, Talens RP et al. DNA methylation differences after exposure to prenatal famine are common and timing- and sex-specific. Hum Mol Genet 2009: 18: 4046-4053.
37. Mattson MP, Shea TB. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci 2003: 26: 137-146.
38. Roth TL, David Sweatt J. Annual Research Review: Epigenetic mechanisms and environmental shaping of the brain during sensitive periods of development. J Child Psychol Psychiatry 2011: 52: 398-408.
39. Amir RE, Van den Veyver IB, Wan M et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 1999: 23: 185-188.
40. Ashley CT, Sutcliffe JS, Kunst CB et al. Human and murine FMR-1: alternative splicing and translational initiation downstream of the CGG-repeat. Nat Genet 1993: 4: 244-251.
41. Gecz J, Gedeon AK, Sutherland GR, Mulley JC. Identification of the gene FMR2, associated with FRAXE mental retardation. Nat Genet 1996: 13: 105-108.
42. Gu Y, Shen Y, Gibbs RA, Nelson DL. Identification of FMR2, a novel gene associated with the FRAXE CCG repeat and CpG island. Nat Genet 1996: 13: 109-113.
43. Movassagh M, Choy MK, Goddard M et al. Differential DNA methylation correlates with differential expression of angiogenic factors in human heart failure. PLoS ONE 2010: 5: e8564.
44. Barres R, Zierath JR. DNA methylation in metabolic disorders. Am J Clin Nutr 2011: 93: 897S-900S.
45. Day JJ, Sweatt JD. DNA methylation and memory formation. Nat Neurosci 2010: 13: 1319-1323.
46. Sherrington R, Rogaev EI, Liang Y et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995: 375: 754-760.
47. Rogaev EI, Sherrington R, Rogaeva EA et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1995: 376: 775-778.
48. Levy-Lahad E, Wasco W, Poorkaj P et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995: 269: 973-977.
49. Goate A, Chartier-Harlin MC, Mullan M et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991: 349: 704-706.
50. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002: 297: 353-356.
51. Scheuner D, Eckman C, Jensen M et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996: 2: 864-870.
52. Rovelet-Lecrux A, Hannequin D, Raux G et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 2006: 38: 24-26.
53. Rovelet-Lecrux A, Frebourg T, Tuominen H et al. APP locus duplication in a Finnish family with dementia and intracerebral haemorrhage. J Neurol Neurosurg Psychiatry 2007: 78: 1158-1159.
54. Bird TD. Genetic factors in Alzheimer's disease. N Engl J Med 2005: 352: 862-864.
55. Corder EH, Saunders AM, Strittmatter WJ et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993: 261: 921-923.
56. Harold D, Abraham R, Hollingworth P et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009: 41: 1088-1093.
57. Lambert JC, Heath S, Even G et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009: 41: 1094-1099.
58. Naj AC, Beecham GW, Martin ER et al. Dementia revealed: novel chromosome 6 locus for late-onset Alzheimer disease provides genetic evidence for folate-pathway abnormalities. PLoS Genet 2010: 6: e1001130.
59. Seshadri S, Beiser A, Selhub J et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002: 346: 476-483.
60. Kronenberg G, Colla M, Endres M. Folic acid, neurodegenerative and neuropsychiatric disease. Curr Mol Med 2009: 9: 315-323.
61. Mattson MP, Magnus T. Ageing and neuronal vulnerability. Nat Rev Neurosci 2006: 7: 278-294.
62. Silverman JM, Ciresi G, Smith CJ, Marin DB, Schnaider-Beeri M. Variability of familial risk of Alzheimer disease across the late life span. Arch Gen Psychiatry 2005: 62: 565-573.
63. Hayden KM, Norton MC, Darcey D et al. Occupational exposure to pesticides increases the risk of incident AD: the Cache County study. Neurology 2010: 74: 1524-1530.
64. Santibanez M, Bolumar F, Garcia AM. Occupational risk factors in Alzheimer's disease: a review assessing the quality of published epidemiological studies. Occup Environ Med 2007: 64: 723-732.
65. Perry VH, Cunningham C, Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol 2007: 7: 161-167.
66. Luchsinger JA, Gustafson DR. Adiposity and Alzheimer's disease. Curr Opin Clin Nutr Metab Care 2009: 12: 15-21.
67. Scarmeas N, Luchsinger JA, Schupf N et al. Physical activity, diet, and risk of Alzheimer disease. JAMA 2009: 302: 627-637.
68. Sanyal J, Chakraborty DP, Sarkar B et al. Environmental and familial risk factors of Parkinsons disease: case-control study. Can J Neurol Sci 2010: 37: 637-642.
69. Firestone JA, Smith-Weller T, Franklin G et al. Pesticides and risk of Parkinson disease: a population-based case-control study. Arch Neurol 2005: 62: 91-95.
70. Priyadarshi A, Khuder SA, Schaub EA, Priyadarshi SS. Environmental risk factors and Parkinson's disease: a metaanalysis. Environ Res 2001: 86: 122-127.
71. Gao X, Chen H, Fung TT et al. Prospective study of dietary pattern and risk of Parkinson disease. Am J Clin Nutr 2007: 86: 1486-1494.
72. Allam MF, Campbell MJ, Hofman A, Del Castillo AS, Fernandez-Crehuet Navajas R. Smoking and Parkinson's disease: systematic review of prospective studies. Mov Disord 2004: 19: 614-621.
73. Hu G, Bidel S, Jousilahti P, Antikainen R, Tuomilehto J. Coffee and tea consumption and the risk of Parkinson's disease. Mov Disord 2007: 22: 2242-2248.
74. Polymeropoulos MH, Lavedan C, Leroy E et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997: 276: 2045-2047.
75. Paisan-Ruiz C, Jain S, Evans EW et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004: 44: 595-600.
76. Kitada T, Asakawa S, Hattori N et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998: 392: 605-608.
77. Valente EM, Abou-Sleiman PM, Caputo V et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004: 304: 1158-1160.
78. Bonifati V, Rizzu P, van Baren MJ et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003: 299: 256-259.
79. Maraganore DM, Farrer MJ, Hardy JA et al. Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology 1999: 53: 1858-1860.
80. Healy DG, Abou-Sleiman PM, Casas JP et al. UCHL-1 is not a Parkinson's disease susceptibility gene. Ann Neurol 2006: 59: 627-633.
81. Lautier C, Goldwurm S, Durr A et al. Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease. Am J Hum Genet 2008: 82: 822-833.
82. Strauss KM, Martins LM, Plun-Favreau H et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet 2005: 14: 2099-2111.
83. Kruger R, Sharma M, Riess O et al. A large-scale genetic association study to evaluate the contribution of Omi/HtrA2 (PARK13) to Parkinson's disease. Neurobiol Aging 2011: 32: 548.e9-548.e18.
84. Ramirez A, Heimbach A, Grundemann J et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 2006: 38: 1184-1191.
85. Morgan NV, Westaway SK, Morton JE et al. PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat Genet 2006: 38: 752-754.
86. Di Fonzo A, Dekker MC, Montagna P et al. FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome. Neurology 2009: 72: 240-245.
87. Kruger R, Vieira-Saecker AM, Kuhn W et al. Increased susceptibility to sporadic Parkinson's disease by a certain combined alpha-synuclein/apolipoprotein E genotype. Ann Neurol 1999: 45: 611-617.
88. Skipper L, Wilkes K, Toft M et al. Linkage disequilibrium and association of MAPT H1 in Parkinson disease. Am J Hum Genet 2004: 75: 669-677.
89. Gilks WP, Abou-Sleiman PM, Gandhi S et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005: 365: 415-416.
90. Lwin A, Orvisky E, Goker-Alpan O, LaMarca ME, Sidransky E. Glucocerebrosidase mutations in subjects with parkinsonism. Mol Genet Metab 2004: 81: 70-73.
91. Ibanez P, Bonnet AM, Debarges B et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 2004: 364: 1169-1171.
92. Chartier-Harlin MC, Kachergus J, Roumier C et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004: 364: 1167-1169.
93. Singleton AB, Farrer M, Johnson J et al. Alpha-synuclein locus triplication causes Parkinson's disease. Science 2003: 302: 841.
94. Zimprich A, Muller-Myhsok B, Farrer M et al. The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am J Hum Genet 2004: 74: 11-19.
95. Antequera F, Bird A. CpG islands. EXS 1993: 64: 169-185.
96. Takai D, Jones PA. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A 2002: 99: 3740-3745.
97. Saxonov S, Berg P, Brutlag DL. A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc Natl Acad Sci U S A 2006: 103: 1412-1417.
98. Weber M, Hellmann I, Stadler MB et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 2007: 39: 457-466.
99. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 2007: 16 Spec No 1: R50-R59.
100. Lopez-Serra L, Esteller M. Proteins that bind methylated DNA and human cancer: reading the wrong words. Br J Cancer 2008: 98: 1881-1885.
101. Riggs AD, Xiong Z, Wang L, LeBon JM. Methylation dynamics, epigenetic fidelity and X chromosome structure. Novartis Found Symp 1998: 214: 214-225; discussion 225-232.
102. Jones PA, Takai D. The role of DNA methylation in mammalian epigenetics. Science 2001: 293: 1068-1070.
103. Kuroda A, Rauch TA, Todorov I et al. Insulin gene expression is regulated by DNA methylation. PLoS ONE 2009: 4: e6953.
104. Irizarry RA, Ladd-Acosta C, Wen B et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009: 41: 178-186.
105. Hellman A, Chess A. Gene body-specific methylation on the active X chromosome. Science 2007: 315: 1141-1143.
106. Zilberman D, Gehring M, Tran RK, Ballinger T, Henikoff S. Genome-wide analysis of Arabidopsis thaliana DNA methylation uncovers an interdependence between methylation and transcription. Nat Genet 2007: 39: 61-69.
107. Rauch TA, Wu X, Zhong X, Riggs AD, Pfeifer GP. A human B cell methylome at 100-base pair resolution. Proc Natl Acad Sci U S A 2009: 106: 671-678.
108. Gama-Sosa MA, Midgett RM, Slagel VA et al. Tissue-specific differences in DNA methylation in various mammals. Biochim Biophys Acta 1983: 740: 212-219.
109. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002: 16: 6-21.
110. Ehrlich M, Gama-Sosa MA, Huang LH et al. Amount and distribution of 5-methylcytosine in human DNA from different types of tissues of cells. Nucleic Acids Res 1982: 10: 2709-2721.
111. Tawa R, Ono T, Kurishita A, Okada S, Hirose S. Changes of DNA methylation level during pre- and postnatal periods in mice. Differentiation 1990: 45: 44-48.
112. Ladd-Acosta C, Pevsner J, Sabunciyan S et al. DNA methylation signatures within the human brain. Am J Hum Genet 2007: 81: 1304-1315.
113. Miller CA, Sweatt JD. Covalent modification of DNA regulates memory formation. Neuron 2007: 53: 857-869.
114. Lubin FD, Sweatt JD. The IkappaB kinase regulates chromatin structure during reconsolidation of conditioned fear memories. Neuron 2007: 55: 942-957.
115. Lubin FD, Roth TL, Sweatt JD. Epigenetic regulation of BDNF gene transcription in the consolidation of fear memory. J Neurosci 2008: 28: 10576-10586.
116. Vanyushin BF, Nemirovsky LE, Klimenko VV, Vasiliev VK, Belozersky AN. The 5-methylcytosine in DNA of rats. Tissue and age specificity and the changes induced by hydrocortisone and other agents. Gerontologia 1973: 19: 138-152.
117. Wilson VL, Smith RA, Ma S, Cutler RG. Genomic 5-methyldeoxycytidine decreases with age. J Biol Chem 1987: 262: 9948-9951.
118. Fuke C, Shimabukuro M, Petronis A et al. Age related changes in 5-methylcytosine content in human peripheral leukocytes and placentas: an HPLC-based study. Ann Hum Genet 2004: 68: 196-204.
119. Suzuki T, Fujii M, Ayusawa D. Demethylation of classical satellite 2 and 3 DNA with chromosomal instability in senescent human fibroblasts. Exp Gerontol 2002: 37: 1005-1014.
120. Jintaridth P, Mutirangura A. Distinctive patterns of age-dependent hypomethylation in interspersed repetitive sequences. Physiol Genomics 2010: 41: 194-200.
121. Issa JP. Age-related epigenetic changes and the immune system. Clin Immunol 2003: 109: 103-108.
122. Kwabi-Addo B, Chung W, Shen L et al. Age-related DNA methylation changes in normal human prostate tissues. Clin Cancer Res 2007: 13: 3796-3802.
123. Tra J, Kondo T, Lu Q et al. Infrequent occurrence of age-dependent changes in CpG island methylation as detected by restriction landmark genome scanning. Mech Ageing Dev 2002: 123: 1487-1503.
124. Christensen BC, Houseman EA, Marsit CJ et al. Aging and environmental exposures alter tissue-specific DNA methylation dependent upon CpG island context. PLoS Genet 2009: 5: e1000602.
125. Bjornsson HT, Sigurdsson MI, Fallin MD et al. Intra-individual change over time in DNA methylation with familial clustering. JAMA 2008: 299: 2877-2883.
126. Lister R, Ecker JR. Finding the fifth base: genome-wide sequencing of cytosine methylation. Genome Res 2009: 19: 959-966.
127. Laurent L, Wong E, Li G et al. Dynamic changes in the human methylome during differentiation. Genome Res 2010: 20: 320-331.
128. Kriaucionis S, Heintz N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 2009: 324: 929-930.
129. Frommer M, McDonald LE, Millar DS et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A 1992: 89: 1827-1831.
130. Bibikova M, Fan JB. Genome-wide DNA methylation profiling. Wiley Interdiscip Rev Syst Biol Med 2010: 2: 210-223.
131. Hu M, Yao J, Polyak K. Methylation-specific digital karyotyping. Nat Protoc 2006: 1: 1621-1636.
132. Down TA, Rakyan VK, Turner DJ et al. A Bayesian deconvolution strategy for immunoprecipitation-based DNA methylome analysis. Nat Biotechnol 2008: 26: 779-785.
133. Lister R, O'Malley RC, Tonti-Filippini J et al. Highly integrated single-base resolution maps of the epigenome in Arabidopsis. Cell 2008: 133: 523-536.
134. Lister R, Pelizzola M, Dowen RH et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009: 462: 315-322.
135. Brouwers N, Sleegers K, Engelborghs S et al. Genetic risk and transcriptional variability of amyloid precursor protein in Alzheimer's disease. Brain 2006: 129: 2984-2991.
136. Milici A, Salbaum JM, Beyereuther K. Study of the Alzheimer's A4 precursor gene promoter region by genomic sequencing using Taq polymerase. Biochem Biophys Res Commun 1990: 169: 46-50.
137. West RL, Lee JM, Maroun LE. Hypomethylation of the amyloid precursor protein gene in the brain of an Alzheimer's disease patient. J Mol Neurosci 1995: 6: 141-146.
138. Tohgi H, Utsugisawa K, Nagane Y et al. Reduction with age in methylcytosine in the promoter region - 224 approximately - 101 of the amyloid precursor protein gene in autopsy human cortex. Brain Res Mol Brain Res 1999: 70: 288-292.
139. Brohede J, Rinde M, Winblad B, Graff C. A DNA methylation study of the amyloid precursor protein gene in several brain regions from patients with familial Alzheimer disease. J Neurogenet 2010: 24: 179-181.
140. Barrachina M, Ferrer I. DNA methylation of Alzheimer disease and tauopathy-related genes in postmortem brain. J Neuropathol Exp Neurol 2009: 68: 880-891.
141. Wang SC, Oelze B, Schumacher A. Age-specific epigenetic drift in late-onset Alzheimer's disease. PLoS ONE 2008: 3: e2698.
142. Hellstrom-Lindahl E, Ravid R, Nordberg A. Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: inverse correlation with A beta levels. Neurobiol Aging 2008: 29: 210-221.
143. Wang S, Wang R, Chen L et al. Expression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme in prospectively studied elderly and Alzheimer's brain. J Neurochem 2010: 115: 47-57.
144. Wang DS, Lipton RB, Katz MJ et al. Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging. J Neuropathol Exp Neurol 2005: 64: 378-385.
145. Yasojima K, Akiyama H, McGeer EG, McGeer PL. Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide. Neurosci Lett 2001: 297: 97-100.
146. Chen KL, Wang SS, Yang YY et al. The epigenetic effects of amyloid-beta(1-40) on global DNA and neprilysin genes in murine cerebral endothelial cells. Biochem Biophys Res Commun 2009: 378: 57-61.
147. Uematsu F, Takahashi M, Yoshida M, Igarashi M, Nakae D. Methylation of neutral endopeptidase 24.11 promoter in rat hepatocellular carcinoma. Cancer Sci 2006: 97: 611-617.
148. Belyaev ND, Nalivaeva NN, Makova NZ, Turner AJ. Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease. EMBO Rep 2009: 10: 94-100.
149. Kalman J, Kitajka K, Pakaski M et al. Gene expression profile analysis of lymphocytes from Alzheimer's patients. Psychiatr Genet 2005: 15: 1-6.
150. Silva PN, Gigek CO, Leal MF et al. Promoter methylation analysis of SIRT3, SMARCA5, HTERT and CDH1 genes in aging and Alzheimer's disease. J Alzheimers Dis 2008: 13: 173-176.
151. Ulrey CL, Liu L, Andrews LG, Tollefsbol TO. The impact of metabolism on DNA methylation. Hum Mol Genet 2005: 14 Spec No 1: R139-R147.
152. Morris MS. Homocysteine and Alzheimer's disease. Lancet Neurol 2003: 2: 425-428.
153. Gillette Guyonnet S, Abellan Van Kan G, Andrieu S et al. IANA task force on nutrition and cognitive decline with aging. J Nutr Health Aging 2007: 11: 132-152.
154. Haan MN, Miller JW, Aiello AE et al. Homocysteine, B vitamins, and the incidence of dementia and cognitive impairment: results from the Sacramento Area Latino Study on Aging. Am J Clin Nutr 2007: 85: 511-517.
155. McCaddon A, Davies G, Hudson P, Tandy S, Cattell H. Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry 1998: 13: 235-239.
156. Clarke R, Smith AD, Jobst KA et al. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998: 55: 1449-1455.
157. McIlroy SP, Dynan KB, Lawson JT, Patterson CC, Passmore AP. Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland. Stroke 2002: 33: 2351-2356.
158. Van Dam F, Van Gool WA. Hyperhomocysteinemia and Alzheimer's disease: a systematic review. Arch Gerontol Geriatr 2009: 48: 425-430.
159. Kennedy BP, Bottiglieri T, Arning E et al. Elevated S-adenosylhomocysteine in Alzheimer brain: influence on methyltransferases and cognitive function. J Neural Transm 2004: 111: 547-567.
160. Fuso A, Nicolia V, Cavallaro RA, Scarpa S. DNA methylase and demethylase activities are modulated by one-carbon metabolism in Alzheimer's disease models. J Nutr Biochem 2011: 22: 242-251.
161. Fuso A, Seminara L, Cavallaro RA, D'Anselmi F, Scarpa S. S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. Mol Cell Neurosci 2005: 28: 195-204.
162. Fuso A, Cavallaro RA, Zampelli A et al. Gamma-secretase is differentially modulated by alterations of homocysteine cycle in neuroblastoma and glioblastoma cells. J Alzheimers Dis 2007: 11: 275-290.
163. Fuso A, Nicolia V, Cavallaro RA et al. B-vitamin deprivation induces hyperhomocysteinemia and brain S-adenosylhomocysteine, depletes brain S-adenosylmethionine, and enhances PS1 and BACE expression and amyloid-beta deposition in mice. Mol Cell Neurosci 2008: 37: 731-746.
164. Fuso A, Nicolia V, Pasqualato A et al. Changes in presenilin 1 gene methylation pattern in diet-induced B vitamin deficiency. Neurobiol Aging 2009: 32: 187-199.
165. Lin HC, Hsieh HM, Chen YH, Hu ML. S-adenosylhomocysteine increases beta-amyloid formation in BV-2 microglial cells by increased expressions of beta-amyloid precursor protein and presenilin 1 and by hypomethylation of these gene promoters. Neurotoxicology 2009: 30: 622-627.
166. Minagawa H, Watanabe A, Akatsu H et al. Homocysteine, another risk factor for Alzheimer disease, impairs apolipoprotein E3 function. J Biol Chem 2010: 285: 38382-38388.
167. Wu J, Basha MR, Brock B et al. Alzheimer's disease (AD)-like pathology in aged monkeys after infantile exposure to environmental metal lead (Pb): evidence for a developmental origin and environmental link for AD. J Neurosci 2008: 28: 3-9.
168. Li YY, Chen T, Wan Y, Xu SQ. Lead exposure in pheochromocytoma cells induces persistent changes in amyloid precursor protein gene methylation patterns. Environ Toxicol 2010, doi: 10.1002/tox.20666.
169. Zawia NH, Lahiri DK, Cardozo-Pelaez F. Epigenetics, oxidative stress, and Alzheimer disease. Free Radic Biol Med 2009: 46: 1241-1249.
170. Blandini F, Fancellu R, Martignoni E et al. Plasma homocysteine and l-dopa metabolism in patients with Parkinson disease. Clin Chem 2001: 47: 1102-1104.
171. Yasui K, Kowa H, Nakaso K, Takeshima T, Nakashima K. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology 2000: 55: 437-440.
172. Duan W, Ladenheim B, Cutler RG et al. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem 2002: 80: 101-110.
173. Jowaed A, Schmitt I, Kaut O, Wullner U. Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains. J Neurosci 2010: 30: 6355-6359.
174. Chiba-Falek O, Lopez GJ, Nussbaum RL. Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients. Mov Disord 2006: 21: 1703-1708.
175. Grundemann J, Schlaudraff F, Haeckel O, Liss B. Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease. Nucleic Acids Res 2008: 36: e38.
176. Pieper HC, Evert BO, Kaut O et al. Different methylation of the TNF-alpha promoter in cortex and substantia nigra: implications for selective neuronal vulnerability. Neurobiol Dis 2008: 32: 521-527.
177. Mastroeni D, McKee A, Grover A, Rogers J, Coleman PD. Epigenetic differences in cortical neurons from a pair of monozygotic twins discordant for Alzheimer's disease. PLoS ONE 2009: 4: e6617.
178. Mastroeni D, Grover A, Delvaux E et al. Epigenetic changes in Alzheimer's disease: decrements in DNA methylation. Neurobiol Aging 2010: 31: 2025-2037.
179. Lewin J, Schmitt AO, Adorjan P, Hildmann T, Piepenbrock C. Quantitative DNA methylation analysis based on four-dye trace data from direct sequencing of PCR amplificates. Bioinformatics 2004: 20: 3005-3012.
180. Simon-Sanchez J, Schulte C, Bras JM et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009: 41: 1308-1312.
181. Hamza TH, Zabetian CP, Tenesa A et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet 2010: 42: 781-785.
182. Seshadri S, Fitzpatrick AL, Ikram MA et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 2010: 303: 1832-1840.
183. Grupe A, Abraham R, Li Y et al. Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants. Hum Mol Genet 2007: 16: 865-873.
184. Kehoe PG, Russ C, McIlory S et al. Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. Nat Genet 1999: 21: 71-72.
185. Gunther C, von Hadeln K, Muller-Thomsen T et al. Possible association of mitochondrial transcription factor A (TFAM) genotype with sporadic Alzheimer disease. Neurosci Lett 2004: 369: 219-223.
186. Crawford FC, Freeman MJ, Schinka JA et al. A polymorphism in the cystatin C gene is a novel risk factor for late-onset Alzheimer's disease. Neurology 2000: 55: 763-768.
187. Scherzer CR, Offe K, Gearing M et al. Loss of apolipoprotein E receptor LR11 in Alzheimer disease. Arch Neurol 2004: 61: 1200-1205.
188. Cook LJ, Ho LW, Taylor AE et al. Candidate gene association studies of the alpha 4 (CHRNA4) and beta 2 (CHRNB2) neuronal nicotinic acetylcholine receptor subunit genes in Alzheimer's disease. Neurosci Lett 2004: 358: 142-146.
189. Grupe A, Li Y, Rowland C et al. A scan of chromosome 10 identifies a novel locus showing strong association with late-onset Alzheimer disease. Am J Hum Genet 2006: 78: 78-88.
190. Biffi A, Anderson CD, Desikan RS et al. Genetic variation and neuroimaging measures in Alzheimer disease. Arch Neurol 2010: 67: 677-685.
191. Reiman EM, Webster JA, Myers AJ et al. GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron 2007: 54: 713-720.
192. Cummings JL. Alzheimer's disease. N Engl J Med 2004: 351: 56-67.
193. Letenneur L. Risk of dementia and alcohol and wine consumption: a review of recent results. Biol Res 2004: 37: 189-193.
194. Garcia AM, Ramon-Bou N, Porta M. Isolated and joint effects of tobacco and alcohol consumption on risk of Alzheimer's disease. J Alzheimers Dis 2010: 20: 577-586.
195. Harwood DG, Kalechstein A, Barker WW et al. The effect of alcohol and tobacco consumption, and apolipoprotein E genotype, on the age of onset in Alzheimer's disease. Int J Geriatr Psychiatry 2010: 25: 511-518.
196. Van Den Heuvel C, Thornton E, Vink R. Traumatic brain injury and Alzheimer's disease: a review. Prog Brain Res 2007: 161: 303-316.
197. Khandhar SM, Marks WJ. Epidemiology of Parkinson's disease. Dis Mon 2007: 53: 200-205.